Short Interest in Celularity, Inc. (NASDAQ:CELU) Drops By 12.9%

Celularity, Inc. (NASDAQ:CELU) was the recipient of a large decrease in short interest during the month of February. As of February 27th, there was short interest totaling 309,422 shares, a decrease of 12.9% from the February 12th total of 355,364 shares. Based on an average trading volume of 38,098 shares, the days-to-cover ratio is currently 8.1 days. Approximately 1.3% of the shares of the stock are short sold. Approximately 1.3% of the shares of the stock are short sold. Based on an average trading volume of 38,098 shares, the days-to-cover ratio is currently 8.1 days.

Celularity Stock Performance

NASDAQ:CELU traded up $0.04 on Tuesday, hitting $1.28. 30,226 shares of the stock were exchanged, compared to its average volume of 180,271. Celularity has a 52 week low of $1.01 and a 52 week high of $4.35. The stock has a market capitalization of $36.92 million, a price-to-earnings ratio of -0.38 and a beta of 0.79. The company’s 50-day moving average price is $1.27 and its 200 day moving average price is $1.69.

Hedge Funds Weigh In On Celularity

Large investors have recently bought and sold shares of the business. Perennial Investment Advisors LLC bought a new position in Celularity in the third quarter valued at approximately $28,000. XTX Topco Ltd bought a new stake in shares of Celularity during the 4th quarter valued at $33,000. Acadian Asset Management LLC acquired a new position in shares of Celularity in the 1st quarter valued at $34,000. Jane Street Group LLC acquired a new position in shares of Celularity in the 4th quarter valued at $46,000. Finally, Bank of America Corp DE boosted its position in shares of Celularity by 1,538.1% in the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after purchasing an additional 35,023 shares during the last quarter. 19.02% of the stock is currently owned by institutional investors and hedge funds.

About Celularity

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.